(Q56373211)

0 references

Ann-Lii Cheng

0 references

Anthony B El-Khoueiry

0 references

Baek-Yeol Ryoo

0 references

Irfan Cicin

0 references

Philippe Merle

0 references

YenHsun Chen

0 references

Joong-Won Park

0 references

Jean-Frederic Blanc

0 references

Luigi Bolondi

0 references

Heinz-Josef Klümpen

0 references

Stephen L Chan

0 references

Tiziana Pressiani

0 references

Min-Hee Ryu

0 references

Alan P Venook

0 references

Colin Hessel

0 references

Anne E Borgman-Hagey

0 references

Gisela Schwab

0 references

Robin K Kelley

The New England Journal of Medicine

0 references

language of work or name

English

0 references

publication date

5 July 2018

0 references

published in

0 references

volume

379

0 references

issue

0 references

page(s)

54-63

0 references

cites work

Interim analysis: the alpha spending function approach.

1 reference

12 December 2020

Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma

1 reference

12 December 2020

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

1 reference

12 December 2020

Sorafenib in advanced hepatocellular carcinoma

1 reference

12 December 2020

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

12 December 2020

NCCN clinical practice guidelines in oncology: hepatobiliary cancers

1 reference

12 December 2020

HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors

1 reference

12 December 2020

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

1 reference

12 December 2020

Targeting MET in cancer: rationale and progress

1 reference

12 December 2020

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

1 reference

12 December 2020

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors

1 reference

12 December 2020

The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?

1 reference

12 December 2020

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

1 reference

12 December 2020

Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.

1 reference

12 December 2020

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

1 reference

12 December 2020

The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer.

1 reference

12 December 2020

Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

1 reference

12 December 2020

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

12 December 2020

Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells

1 reference

12 December 2020

Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer

1 reference

12 December 2020

Axl Expression Stratifies Patients with Poor Prognosis after Hepatectomy for Hepatocellular Carcinoma

1 reference

12 December 2020

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.

1 reference

12 December 2020

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

1 reference

12 December 2020

The Receptor Tyrosine Kinase AXL in Cancer Progression

1 reference

12 December 2020

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

12 December 2020

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study

1 reference

12 December 2020

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

1 reference

12 December 2020

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

1 reference

12 December 2020